Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 204 participants.
Also called NCT07041281
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 204 participants
- Sponsor
- Registry
-
NCT07041281
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07041281. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-16 (actual); primary completion 2027-12-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
- Acronym
- IMPACT-HT
- Condition
- Preeclampsia
- Condition
- Gestational Hypertension
- Intervention (Drug)
- spironolactone 25 mg orally once daily
- Intervention (Drug)
- Placebo tablet to match spironolactone
- Lead sponsor
- Massachusetts General Hospital
- Collaborator
- Brigham and Women's Hospital
- Collaborator
- University of Pittsburgh Medical Center
Record details
- Record id
cardio:ct-nct07041281- Content hash
fa9a91aa24fb75f305af0d30f6f17034be3269c1f26f2c15c143ad169a8aa99c